Table 1.

Clinicopathological characteristics and extent of expression of FasL and FasR in breast tumors

PatientTumor typeGradeaExtent of expressionb
1Intraduct and infiltrating carcinoma3++++++
2Intraduct and infiltrating carcinoma3+++++++
3Intraduct and infiltrating carcinoma2++++++++
4Intraduct and infiltrating carcinoma3++++++
5Intraduct and infiltrating carcinoma2++++++++
6Intraduct and infiltrating carcinoma2++++++++
7Infiltrative ductal carcinoma2++++++
8Infiltrative ductal carcinoma1+++++++
9Infiltrative ductal carcinoma2++++++
10Ductal carcinoma in situNAc+++++++
11Ductal carcinoma in situNA++++++++
12Ductal carcinoma in situNA+++++++
13Infiltrative mucinous carcinomaLowd++++++
14Mucinous adenocarcinomaNDe+++++++
15Infiltrative lobular carcinoma2++++++
16Infiltrative lobular carcinoma2++++++
17Tubular carcinoma1++++++
  • a Graded by the Nottingham modification of Scarrf-Bloom-Richardson.

  • b Extent of expression was graded on the basis of the percentage of positive cells, as follows: +, 0 to 25%; ++, 25 to 50%; +++, 50 to 75%; ++++, 75 to 100%.

  • c NA, not applicable.

  • d Graded by conventional histopathological classification.

  • e ND, not determined.